This is the authors' abstract. We don't add key points for this paper.
Cancer cachexia is a prevalent and currently untreatable metabolic syndrome in advanced cancer, characterized by severe skeletal muscle and adipose wasting and increased cancer-related mortality. Emerging evidence suggests that epigenetic dysregulation is an important contributor to its pathogenesis. This review summarizes the key epigenetic mechanisms underlying cachectic tissue atrophy. Aberrant histone acetylation and methylation (via HDAC4, p300, SMYD3, etc .) up-regulate atrophy-associated gene expression, whereas dysregulated SENP3-mediated SUMOylation impairs sarcomere integrity. DNMT3a down-regulation-associated DNA hypomethylation exacerbates muscle loss through DDIT4, and tumor-secreted miR-223-5p disrupts m 6 A modification via METTL14 suppression, thereby enhancing proteolysis. Non-coding RNAs (miRNAs, lncRNAs, and circRNAs) mediate tumor-host crosstalk and form an interconnected catabolic network. These largely preclinical findings identify HDACs, DNMTs, and m 6 A regulators as promising therapeutic targets and biomarkers, although their clinical relevance requires further validation. Future research should prioritize translating these epigenetic insights into clinical applications, including combination strategies that target interconnected epigenetic networks to address this unmet clinical need.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: